Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

NCT00562068 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Small Intestine Cancer

Interventions

BIOLOGICAL: alemtuzumab
DRUG: cyclophosphamide
DRUG: doxorubicin hydrochloride
DRUG: prednisolone
DRUG: vincristine sulfate
GENETIC: polymerase chain reaction
OTHER: flow cytometry
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

Cancer Research UK